March 16, 2024Open Access

Persistent COVID-19 parosmia and olfactory loss post olfactory training: randomized clinical trial comparing central and peripheral-acting therapeutics

Key Points

Key points are not available for this paper at this time.

Abstract

Although COVID-19 anosmia is often transient, patients with persistent olfactory dysfunction (pOD) can experience refractory parosmia and diminished smell. This study evaluated four putative therapies for parosmia in patients with chronic COVID-19 olfactory impairment.

KI fragen

Bookmark

View Full Paper

Cite This Study

Cantone et al. (Sat,) studied this question.

synapsesocial.com/papers/68e73b96b6db6435876b5018 https://doi.org/https://doi.org/10.1007/s00405-024-08548-6

KI fragen

Bookmark

View Full Paper